hiv-1

Documents about hiv-1

• Social and Genetic Networks of HIV-1 Transmission in New York City#491877eScholarship
• A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection#980328ClinicalTrials.gov
• QoALa: A comprehensive workflow for viral quasispecies diversity comparison using long-read sequencing data#141252PLOS
• Paracrine signals from HIV-1-infected immune cells reprogram cervical cancer pathways#485221Europe PMC
• Treatment of AIDS and AIDS Related Complex. Part-1- Treatment of Patients With ARC (AZT Vs. Placebo)#882926ClinicalTrials.gov
• Analysis of Data Collected From Individuals Administered Neurobehavioral Assessments#1009540ClinicalTrials.gov
• Variation in HIV-1 Nef function within and among viral subtypes reveals genetically separable antagonism of SERINC3 and SERINC5#609403eScholarship
• SMAC mimetics induce autophagy-dependent apoptosis of HIV-1-infected macrophages#619969eScholarship
• Molecular Regulation of HIV-1 Expression and Persistence Across Diverse Cellular Reservoirs#67594Europe PMC
• A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644)#829909ClinicalTrials.gov
• Diethylhomospermine (DEHSPM) for Refractory AIDS-Related Diarrhea#860376ClinicalTrials.gov
• The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection#1032792ClinicalTrials.gov
• Geospatial and temporal analysis of HIV-1 viral loads and drug resistance in Kwazulu-Natal, South Africa.#327902ResearchSpace
• Reaching 90 90 90 in Adolescents in Zambia: Using All Our SKILLZ#884078ClinicalTrials.gov
• A Single Dose of Pembrolizumab in HIV-Infected People#893438ClinicalTrials.gov
• 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada#620034eScholarship
• Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in HIV-1–Infected Women#642151eScholarship
• A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)#180206ClinicalTrials.gov
• HIV efficiently infects T cells from the endometrium and remodels them to promote systemic viral spread#609389eScholarship
• HIV-related mortality time trends among children and young adolescents on antiretroviral therapy by age, treatment duration, and region: a systematic review and meta-regression analysis#142482HAL (France)
• Experimental and MEDT Study of Sydnone–Alkyne Cycloaddition-Based Synthesis of 1,4-Disubstituted Pyrazoles and In Silico Investigation of Their Binding to HCV and HIV Proteins#235123HAL (France)
• Characterization of HIV-1 Env found in virus reservoirs in lymph nodes and peripheral blood.#243040ResearchSpace
• Additional file 1: of Comparing research investment to United Kingdom institutions and published outputs for tuberculosis, HIV and malaria: a systematic analysis across 1997–2013#304857LSHTM Data Compass
• Spatiotemporal dynamics of HIV-1 transmission in France (1999–2014) and impact of targeted prevention strategies#491876eScholarship
• A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy#802954ClinicalTrials.gov
• TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use#1032108ClinicalTrials.gov
• Biomarkers of neuronal injury and amyloid metabolism in the cerebrospinal fluid of patients infected with HIV-1 subtypes B and C#614661eScholarship
• Efficacy and Safety of Switching to Dolutegravir/Lamivudine in Virologically Suppressed HIV-1 Infected Adults with TDF-Related Renal or Bone Toxicity#299105Springer Nature OA
• A TCR-mimic bispecific antibody reduces HIV-1 provirus and delays viral rebound in HLA-matched humanized mice#484965Europe PMC
• Evaluation of neutralization sensitivity of HIV-1 subtype C between plasma, peripheral blood mononuclear cells and lymph node-derived viruses.#631714ResearchSpace
• Tat IRES modulator of tat mRNA (TIM-TAM): a conserved RNA structure that controls Tat expression and acts as a switch for HIV productive and latent infection#257401HAL (France)
• Analysis of correlations between energy and residue fluctuations in native proteins and determination of specific sites for binding#934948Koc University Digital Collections
• Suicide risk and prevalence of major depressive disorder (MDD) among individuals infected with HIV-1 subtype C versus B in Southern Brazil#612041eScholarship
• Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: Brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug#7901HAL (France)
• A snapshot of HIV-1 genetic diversity in Dominican Republic in 2024: Predominance of the BCar lineage and first description of a CRF02-AG isolate#169047Unpaywall
• Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus#811661ClinicalTrials.gov
• Vietnam Cryptococcal Retention in Care Study Version 1.0#900210ClinicalTrials.gov
• PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir#834097ClinicalTrials.gov
• ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy#879547ClinicalTrials.gov
• Characterization of the conformational state and flexibility of HIV-1 glycoprotein gp120 core domain#954416Koc University Digital Collections
• Characterization of Binding and Fusion Efficiencies Mediated by the V1–V5 Env Derived from Transmitted and Non-transmitted Viruses Isolated from a Perinatal Transmission Cohort from Zambia#982858DigitalCommons@University of Nebraska
• A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes#879985ClinicalTrials.gov
• Lenacapavir-induced lattice hyperstabilization is central to HIV-1 capsid failure at the nuclear pore complex and in the cytoplasm#485066Europe PMC
• Safety and Efficacy of Allogenic Adoptive Immune Therapy for Immune Reconstitution in Chronic HIV-1 Infected Patients#854018ClinicalTrials.gov
• Evolution of Human Immunodeficiency Virus Type 1 Clade C Envelope V1–V5 Region during Disease Progression in Non-Human Primate Model#982861DigitalCommons@University of Nebraska
• Estimated mortality on HIV treatment among active patients and patients lost to follow-up in 4 provinces of Zambia: Findings from a multistage sampling-based survey#491814eScholarship
• SPIRIT Checklist for: Efficacy and safety of long acting injectable cabotegravir and rilpivirine in improving HIV-1 control in Sub Saharan Africa: Protocol for a phase 3b open label randomized controlled trial (IMPALA)#348109LSHTM Data Compass
• A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain#806058ClinicalTrials.gov
• HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection#879866ClinicalTrials.gov
• Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs#839925ClinicalTrials.gov